Form 4: Cingulate Inc. Director Jeffrey S. Ervin Acquires Stock Options
SEC Form 4
Director Jeffrey S. Ervin reports acquisition of stock options in Cingulate Inc. following stockholder approval of an amendment to the equity incentive plan.
Summary
- On June 13, 2024, Jeffrey S. Ervin, a director of Cingulate Inc., filed a Form 4 disclosing transactions related to stock options.
- Ervin acquired stock options to purchase 5,000 shares of common stock at an exercise price of $1.18, vesting in two tranches over six and twelve months from the grant date of March 4, 2024.
- He also acquired options for 13,875 shares at $1.18, vesting one year from the grant date of March 4, 2024, issued in lieu of $27,750 in cash retainer fees.
- Additionally, Ervin acquired options for 10,000 shares at $0.70, vesting one year from the grant date of June 12, 2024.
- These options were granted following stockholder approval on June 11, 2024, of Amendment No. 1 to the Cingulate Inc. 2021 Omnibus Equity Incentive Plan.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants to a director, indicating alignment of interests but not necessarily a strong positive or negative signal.
Positives
- The acquisition of stock options by a director signals confidence in the company's future prospects.
- The use of stock options in lieu of cash retainer fees can conserve company cash resources.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedules of the options.
Industry Context
This filing is a routine disclosure of insider transactions, common in the pharmaceutical industry where equity compensation is frequently used to incentivize executives and directors.
Stakeholder Impact
- The granting of stock options aligns the director's interests with those of the shareholders, potentially encouraging decisions that increase shareholder value.
Key Dates
| Date | Description |
|---|---|
| March 4, 2024 | Stock option grant approved by Cingulate Inc.'s board of directors. |
| June 11, 2024 | Cingulate's stockholders approved Amendment No.1 to the Cingulate Inc. 2021 Omnibus Equity Incentive Plan. |
| June 11, 2024 | Earliest transaction date. |
| June 12, 2024 | Date of stock option acquisition with exercise price of $0.70. |
| June 13, 2024 | Date of Form 4 filing. |
| March 4, 2034 | Expiration date for stock options with exercise price of $1.18. |
| June 12, 2034 | Expiration date for stock options with exercise price of $0.70. |
Keywords
stock options, Form 4, Cingulate Inc., director, equity incentive plan, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.